Endocrine Society experts encouraged more widespread screening for a common hormonal cause of high blood pressure known as ...

In recent study, 23 percent of NHANES primary prevention cohort currently using lipid-lowering therapies versus 47 percent eligible under U.S. guidelines.

Finerenone gained FDA approval for heart failure treatment, showcasing significant benefits in reducing cardiovascular events ...